| Name | Title | Contact Details |
|---|
Clear Stone Central Lab is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Max Neeman International is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CGHN has been a trusted partner for Central Georgia independent physicians for over 20 years, with proven success in favorable payouts, dividends and contracting. This commitment to physician independence is at the very heart of CGHN`s identity. CGHN`s ownership structure ensures independent physicians in Central Georgia maintain a strong, controlling governance voice. CGHN is a growing, clinically-integrated network representing nearly 1,000 independent physicians, healthcare professionals and hospital partners across Central Georgia. Our goal is to deliver the best patient care experiences, while enhancing care quality and lowering costs.
Centro Latino de Chelsea is a Chelsea, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.